Homatropine

Summary

Homatropine (CHEMBL1618018) is an approved small molecule (ATC S01FA05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01FA05
• Clinical trials: 1
• Chemistry: 275.34 Da · C16H21NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1618018
Name	Homatropine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282593
ATC	S01FA05
Molecular formula	C16H21NO3
Molecular weight	275.34
InChIKey	ZTVIKZXZYLEVOL-DGKWVBSXSA-N

SMILES: CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O

IUPAC name: [(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate

Also known as: Homatropine, SID144206655, HOMATROPINE, HOMATROPINE BROMIDE, homatropine, Homatropine Bromide

Parent form; salt/anhydrous children: CHEMBL1319362

Patent coverage: 1,613 distinct patent families (6,014 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02344732	Not specified	COMPLETED	Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).